IDO1 and pancreatic neoplasm: Carbidopa, another antiparkinsonian medication, has also been shown to be effective against pancreatic cancer by the inhibition of indoleamine-2,3-dioxygenase-1 and the potentiation of aryl hydrocarbon receptor signaling (36).